 | • レポートコード：MRC2307A0040 • 出版社/出版日：Transparency Market Research / 2023年5月 • レポート形態：英文、PDF、185ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当市場調査書によると、世界のカルシウムチャネル遮断薬市場規模が、2023年の145億ドルから2031年までに240億ドルに達し、予測期間中にCAGR（年平均成長率）5.7%で拡大すると予想されています。本書は、カルシウムチャネル遮断薬の世界市場を総合的に調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、薬剤クラス別（フェニルアルキルアミン、ベンゾチゼピン、ジヒドロピリジン）分析、用途別（高血圧、扁桃炎、不整脈、肥大型心筋症、その他）分析、投与経路別（経口、非経口）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの項目を掲載しています。なお、Pfizer, Inc.、Teva Pharmaceutical Industries Ltd.、Bausch Health Company, Inc.、Novartis AG、AstraZeneca、Merck & Co. Inc.、GSK plc、Bayer AG、Sun Pharmaceutical Industries Ltd.、Daiichi Sankyo Company, Limitedなど、主要企業情報が含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・主要インサイト ・世界のカルシウムチャネル遮断薬市場規模：薬剤クラス別 - フェニルアルキルアミンの市場規模 - ベンゾチゼピンの市場規模 - ジヒドロピリジンの市場規模 ・世界のカルシウムチャネル遮断薬市場規模：用途別 - 高血圧における市場規模 - 扁桃炎における市場規模 - 不整脈における市場規模 - 肥大型心筋症における市場規模 - その他用途における市場規模 ・世界のカルシウムチャネル遮断薬市場規模：投与経路別 - 経口投与における市場規模 - 非経口投与における市場規模 ・世界のカルシウムチャネル遮断薬市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 ・世界のカルシウムチャネル遮断薬市場規模：地域別 - 北米のカルシウムチャネル遮断薬市場規模 - ヨーロッパのカルシウムチャネル遮断薬市場規模 - アジア太平洋のカルシウムチャネル遮断薬市場規模 - 中南米のカルシウムチャネル遮断薬市場規模 - 中東・アフリカのカルシウムチャネル遮断薬市場規模 ・競争状況 |
Calcium Channel Blockers Market – Scope of Report
TMR’s report on the global Calcium Channel Blockers market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Calcium Channel Blockers market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Calcium Channel Blockers market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Calcium Channel Blockers market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Calcium Channel Blockers market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Calcium Channel Blockers market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Calcium Channel Blockers market.
The report delves into the competitive landscape of the global Calcium Channel Blockers market. Key players operating in the global Calcium Channel Blockers market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Calcium Channel Blockers market profiled in this report.
Key Questions Answered in Global Calcium Channel Blockers Market Report
• What is the sales/revenue generated by Calcium Channel Blockers across all regions during the forecast period?
• What are the opportunities in the global Calcium Channel Blockers market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?
Calcium Channel Blockers Market – Research Objectives and Research Approach
The comprehensive report on the global Calcium Channel Blockers market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global Calcium Channel Blockers market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Calcium Channel Blockers market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Calcium Channel Blockers Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Calcium Channel Blockers Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Disease Prevalence & Incidence Rate globally with key countries
5.2. Key product/brand Analysis
5.3. Pipeline Analysis
5.4. COVID-19 Pandemic Impact on Industry
6. Global Calcium Channel Blockers Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017-2031
6.3.1. Phenylalkylamine
6.3.2. Benzothizepine
6.3.3. Dihydropyridine
6.3.3.1. 1st Generation
6.3.3.2. 2nd Generation
6.3.3.3. 3rd Generation
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Calcium Channel Blockers Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017-2031
7.3.1. Hypertension
7.3.2. Angina
7.3.3. Arrhythmia
7.3.4. Hypertrophic Cardiomyopathy
7.3.5. Others (Raynaud’s disease, etc.)
7.4. Market Attractiveness Analysis, by Application
8. Global Calcium Channel Blockers Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2017-2031
8.3.1. Oral
8.3.2. Parenteral
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Calcium Channel Blockers Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Distribution Channel, 2017-2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness Analysis, by Distribution Channel
10. Global Calcium Channel Blockers Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Calcium Channel Blockers Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017-2031
11.2.1. Phenylalkylamine
11.2.2. Benzothizepine
11.2.3. Dihydropyridine
11.2.3.1. 1st Generation
11.2.3.2. 2nd Generation
11.2.3.3. 3rd Generation
11.3. Market Value Forecast, by Application, 2017-2031
11.3.1. Hypertension
11.3.2. Angina
11.3.3. Arrhythmia
11.3.4. Hypertrophic Cardiomyopathy
11.3.5. Others (Raynaud’s disease, etc.)
11.4. Market Value Forecast, by Route of Administration, 2017-2031
11.4.1. Oral
11.4.2. Parenteral
11.5. Market Value Forecast, by Distribution Channel, 2017-2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Application
11.7.3. By Route of Administration
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Calcium Channel Blockers Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017-2031
12.2.1. Phenylalkylamine
12.2.2. Benzothizepine
12.2.3. Dihydropyridine
12.2.3.1. 1st Generation
12.2.3.2. 2nd Generation
12.2.3.3. 3rd Generation
12.3. Market Value Forecast, by Application, 2017-2031
12.3.1. Hypertension
12.3.2. Angina
12.3.3. Arrhythmia
12.3.4. Hypertrophic Cardiomyopathy
12.3.5. Others (Raynaud’s disease, etc.)
12.4. Market Value Forecast, by Route of Administration, 2017-2031
12.4.1. Oral
12.4.2. Parenteral
12.5. Market Value Forecast, by Distribution Channel, 2017-2031
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Drug Class
12.7.2. By Application
12.7.3. By Route of Administration
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Calcium Channel Blockers Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017-2031
13.2.1. Phenylalkylamine
13.2.2. Benzothizepine
13.2.3. Dihydropyridine
13.2.3.1. 1st Generation
13.2.3.2. 2nd Generation
13.2.3.3. 3rd Generation
13.3. Market Value Forecast, by Application, 2017-2031
13.3.1. Hypertension
13.3.2. Angina
13.3.3. Arrhythmia
13.3.4. Hypertrophic Cardiomyopathy
13.3.5. Others (Raynaud’s disease, etc.)
13.4. Market Value Forecast, by Route of Administration, 2017-2031
13.4.1. Oral
13.4.2. Parenteral
13.5. Market Value Forecast, by Distribution Channel, 2017-2031
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Drug Class
13.7.2. By Application
13.7.3. By Route of Administration
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Calcium Channel Blockers Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017-2031
14.2.1. Phenylalkylamine
14.2.2. Benzothizepine
14.2.3. Dihydropyridine
14.2.3.1. 1st Generation
14.2.3.2. 2nd Generation
14.2.3.3. 3rd Generation
14.3. Market Value Forecast, by Application, 2017-2031
14.3.1. Hypertension
14.3.2. Angina
14.3.3. Arrhythmia
14.3.4. Hypertrophic Cardiomyopathy
14.3.5. Others (Raynaud’s disease, etc.)
14.4. Market Value Forecast, by Route of Administration, 2017-2031
14.4.1. Oral
14.4.2. Parenteral
14.5. Market Value Forecast, by Distribution Channel, 2017-2031
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Drug Class
14.7.2. By Application
14.7.3. By Route of Administration
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Calcium Channel Blockers Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Class, 2017-2031
15.2.1. Phenylalkylamine
15.2.2. Benzothizepine
15.2.3. Dihydropyridine
15.2.3.1. 1st Generation
15.2.3.2. 2nd Generation
15.2.3.3. 3rd Generation
15.3. Market Value Forecast, by Application, 2017-2031
15.3.1. Hypertension
15.3.2. Angina
15.3.3. Arrhythmia
15.3.4. Hypertrophic Cardiomyopathy
15.3.5. Others (Raynaud’s disease, etc.)
15.4. Market Value Forecast, by Route of Administration, 2017-2031
15.4.1. Oral
15.4.2. Parenteral
15.5. Market Value Forecast, by Distribution Channel, 2017-2031
15.5.1. Hospital Pharmacies
15.5.2. Retail Pharmacies
15.5.3. Online Pharmacies
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Drug Class
15.7.2. By Application
15.7.3. By Route of Administration
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company, 2022
16.3. Company Profiles
16.3.1. Pfizer, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Teva Pharmaceutical Industries Ltd.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Bausch Health Company, Inc.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Novartis AG
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. AstraZeneca
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Merck & Co. Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. GSK plc
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Bayer AG
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Sun Pharmaceutical Industries Ltd.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Daiichi Sankyo Company, Limited
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
Table 01. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 02. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 03. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 04. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 05. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 06. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 07. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 08. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 09. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 10. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 11. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 12. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 13. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 14. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 15. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 16. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 17. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 18. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 19. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 20. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 21. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 22. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 23. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 24. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 25. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 26. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
Table 27. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 28. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 29. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 30. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031